This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion ...

AstraZeneca has announced a jump in sales in recent months after a surge in demand for cancer drugs, as the pharmaceutical giant prepares to plug 50 billion dollars (£37 billion) into its US expansion ...

Cambridge headquartered AstraZeneca saw its UK share price rocket 328p to 11,118 and its market cap soar to £173.49 billion after a stunning set of results for the first half and second quarter of ...

Astrazeneca has revealed a jump in revenue from cancer drugs amid rumours its boos is eyeing a listing across the pond. Total ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

Barclays today said half-year pre-tax profits rose 23% to £5.2 billion, boosted by a 28% improvement in the second quarter of ...

Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline ...

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising ...

The Anglo-Swedish pharmaceutical giant said Tuesday that for the second quarter, core earnings per share rose to $2.17 from $1.98 in the same period a year prior. Revenue increased to $14.46 billion ...

Pharmaceutical giant AstraZeneca has reported increased revenue across all its major geographic regions and increased interim profits as the listed business maintained its growth ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...